IDH2 and astrocytoma (excluding glioblastoma): Amplifications of CDK4/6, CCND2, PDGFRA, MYCN as well as RB1 mutation/homozygous deletion, MET alterations, PIK3R1/PIK3CA mutations, NOTCH1 mutations and TCF12 mutations are also associated with tumor progression & shorter survival in IDH mutant astrocytomas (Brat et al., 2020; Li et al., 2019; Broderick et al., 2004; Labreche et al., 2015; Kamoun et al., 2016; Aoki et al., 2018).